Orofacial pain in oncology: use of a new analgesic peptide tafalgin
In patients with head and neck tumors severe pain is more common than in patients with malignant neoplasms of other locations. At a third of patients, pain is the first characteristic of the disease, and after diagnosis, one half of the patients are already having pain syndrome. Аntitumor treatment...
Saved in:
Main Authors: | G. R. Abuzarova, R. R. Sarmanaeva, G. S. Alekseeva, S. V. Kuznetsov, A. R. Gevorkov, N. A. Fedorenko, D. A. Zaretskaya |
---|---|
Format: | Article |
Language: | Russian |
Published: |
ABV-press
2023-12-01
|
Series: | Опухоли головы и шеи |
Subjects: | |
Online Access: | https://ogsh.abvpress.ru/jour/article/view/913 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Tafalgin is a Russian innovative tetrapeptide pharmaceutical for subcutaneous injection: review of the results of phase I and II clinical trials
by: V. S. Kosorukov, et al.
Published: (2022-08-01) -
Cancer patients with chronic pain syndrome: can we improve their quality of life?
by: M. M. Konstantinova, et al.
Published: (2023-06-01) -
New WHO guidelines for cancer pain in adults and adolescents
by: A. D. Kaprin, et al.
Published: (2021-06-01) -
Analgesic and Neuroprotective Roles of Dexmedetomidine in Spine Surgery: A Systematic Review
by: Spyridoula Roberta Afrati, et al.
Published: (2025-07-01) -
ANALYSIS OF PHARMACEUTICAL SUPPORRT OF ONCOLOGICAL PATIENTS WITH NARCOTIC ANALGESICS IN THE OUTPATIENT SETTING IN NIZHNI NOVGOROD
by: S. V. Kononova, et al.
Published: (2015-10-01)